AffiADA® Rituximab (Rituxan) Pharmacokinetic ELISA

Rituximab is a chimeric monoclonal antibody used in the treatment of diseases characterized by abnormal or excessive B cells. Rituximab targets CD20, which is expressed on the surface of B cells, to induce apoptosis in B cells and is used in the treatment of leukemias and lymphomas, some autoimmune disorders, and organ transplant. A quantitative method for Rituximab has been developed and optimized for pharmacokinetic assessment of samples.